OPTIC

OPTIC

Biotechnology Research

San Francisco, CA 1,603 followers

AI-powered drug discovery platform for rapid molecule screening and testing, from target identification to lab validatio

About us

AI-powered drug discovery platform for rapid molecule screening and testing, from target identification to lab validation. Automating biotech R&D. About Optic Optic started as an AI research team developing high-performance similarity search algorithms. Today our proprietary AI-technology is powering products in multiple industries from blockchain to biotech.

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
San Francisco, CA
Type
Privately Held
Founded
2021

Locations

Employees at OPTIC

Updates

  • OPTIC reposted this

    View profile for Andrey Doronichev, graphic

    CEO at Optic, AI Drug Discovery.

    Exciting news: OPTIC won GOLD in BELKA Kaggle – a challenge for AI models to predict new medicines using Leash Bio dataset! We placed 8th out of 2,398 participants! https://lnkd.in/gWuYvPM3 Last night, when Leash Bio published the results, I immediately called my co-founder Vlad Vinogradov to tell him how proud I am of what he has accomplished. This was another amazing validation for the AI team we've assembled and the BIOPTIC platform, our proprietary, target-agnostic AI for small molecule hit identification. The goal of the competition was to predict specific binders for three different targets – sEH, BRD4, and HSA. HSA poses a particular challenge with its three distinct binding sites, complicating predictions for traditional structure-based methods like docking. With BIOPTIC AI, in just two weeks, we were able to find a needle in a haystack of 3.6 billion DEL measurements. Takeaway: If you're utilizing DEL for drug discovery, we should talk. The BIOPTIC platform could offer a game-changing way for you to fully exploit the massive datasets you generate and identify viable drug candidates.

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
  • OPTIC reposted this

    View profile for Andrey Doronichev, graphic

    CEO at Optic, AI Drug Discovery.

    There are two types of AIs in the world: "magic" and "boring." "Magic" AI tools tackle problems beyond human capacity, like predicting protein structures (AlphaFold) or screening billions of molecules swiftly (BIOPTIC). On the other hand, "boring" AIs sometimes show even more impact by automating mundane tasks and eliminating tedious work like emailing CROs to request quotes for synthesizing molecules. At OPTIC, we combine the best of both worlds. While at the core of our BIOPTIC platform is a proprietary model for "magic" small molecule discovery, in our latest release we've added some new "boring" LLM-based workflow automation tools. Our aim? To help biotech R&D teams move faster with AI, whether through extraordinary feats or everyday automation. What's new ◾ BIOPTIC Copilot: An LLM-based agent that automates routine workflows like literature research and can select and use various tools (both internal and external) for drug discovery. Try it for something like “let’s find a drug for Parkinson's.” ◾ BIOPTIC Flows: A workflow automation tool that lets us create pipelines, refine them interactively, and integrate seamlessly into workflows, enhancing productivity and collaboration. ◾ Tanimoto Similarity Search: A textbook similarity search tool that enables exploration of vast chemical spaces by structural similarity. Curious to explore? Visit app.bioptic.io and share your thoughts!

    • No alternative text description for this image

Similar pages